Investors Purchase High Volume of Sarepta Therapeutics Call Options (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was the recipient of some unusual options trading on Tuesday. Traders bought 3,559 call options on the stock. This represents an increase of 71% compared to the average daily volume of 2,081 call options.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wedbush reiterated an “outperform” rating and issued a $224.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 29th. JPMorgan Chase & Co. reduced their price objective on Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating for the company in a research note on Friday, May 3rd. Oppenheimer raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a research note on Tuesday, May 14th. Citigroup raised their price objective on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Finally, UBS Group raised their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $163.94.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $128.30 on Thursday. The firm has a market cap of $12.13 billion, a PE ratio of 1,166.36 and a beta of 0.95. The stock’s fifty day moving average price is $126.95 and its two-hundred day moving average price is $113.71. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $150.16.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business’s revenue was up 63.1% on a year-over-year basis. During the same period in the previous year, the company posted ($1.44) earnings per share. On average, equities research analysts forecast that Sarepta Therapeutics will post 2.68 EPS for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the transaction, the insider now directly owns 18,125 shares in the company, valued at $2,537,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Kathryn Jean Boor sold 761 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total value of $508,900.00. Following the transaction, the insider now owns 18,125 shares of the company’s stock, valued at $2,537,500. The disclosure for this sale can be found here. Over the last three months, insiders sold 25,731 shares of company stock worth $3,248,319. 7.70% of the stock is currently owned by insiders.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in SRPT. Capital International Investors grew its position in Sarepta Therapeutics by 160.0% during the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after buying an additional 2,917,797 shares in the last quarter. Norges Bank purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth about $80,697,000. Bank of Nova Scotia purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth about $50,990,000. Avoro Capital Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 7.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after purchasing an additional 319,444 shares in the last quarter. Finally, Mizuho Markets Americas LLC purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter worth about $29,813,000. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.